{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:41:35Z","timestamp":1782888095823,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,19]]},"DOI":"10.7759\/cureus.33964","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T14:45:22Z","timestamp":1674139522000},"source":"Crossref","is-referenced-by-count":2,"title":["Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II"],"prefix":"10.7759","author":[{"given":"Moises","family":"Enghelberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Kaifee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2011.594202","article-title":"Breast cancer medications and vision: effects of treatments for early-stage disease","volume":"36","author":"Eisner A","year":"2011","unstructured":"Eisner A, Luoh SW. Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res. 2011, 36:867-885. 10.3109\/02713683.2011.594202","journal-title":"Curr Eye Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrc.2015.09.004","article-title":"Docetaxel maculopathy","volume":"7","author":"Haq I","year":"2016","unstructured":"Haq I, Salvi S, Brown L, et al.. Docetaxel maculopathy. Cancer Treatment Communications. 2016, 7:4-7. 10.1016\/j.ctrc.2015.09.004","journal-title":"Cancer Treatment Communications"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0069477011408058.","article-title":"Reporting on adverse clinical events","volume":"49","author":"Culley C","year":"2011","unstructured":"Culley C, Farthing K, Hinthorn D, et al.. Reporting on adverse clinical events. Clin-Alert. 2011, 49:1-8. 10.1177\/0069477011408058.","journal-title":"Clin-Alert"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.46.29049","article-title":"Rek, a gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl\/Tyro3 family","volume":"271","author":"Biscardi JS","year":"1996","unstructured":"Biscardi JS, Denhez F, Buehler GF, et al.. Rek, a gene expressed in retina and brain, encodes a receptor tyrosine kinase of the Axl\/Tyro3 family. J Biol Chem. 1996, 271:29049-29059. 10.1074\/jbc.271.46.29049","journal-title":"J Biol Chem"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1188\/16.ONF.235-243","article-title":"Ocular toxicity of tyrosine kinase inhibitors","volume":"43","author":"Davis ME","year":"2016","unstructured":"Davis ME. Ocular toxicity of tyrosine kinase inhibitors. Oncol Nurs Forum. 2016, 43:235-243. 10.1188\/16.ONF.235-243","journal-title":"Oncol Nurs Forum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/108076803322279426","article-title":"Ocular side-effects associated with imatinib mesylate (Gleevec)","volume":"19","author":"Fraunfelder FW","year":"2003","unstructured":"Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003, 19:371-375. 10.1089\/108076803322279426","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-008-0561-7","article-title":"Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)","volume":"52","author":"Kwon SI","year":"2008","unstructured":"Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008, 52:331-333. 10.1007\/s10384-008-0561-7","journal-title":"Jpn J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645030-00002","article-title":"Clinical pharmacokinetics of docetaxel : recent developments","volume":"45","author":"Baker SD","year":"2006","unstructured":"Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel : recent developments. Clin Pharmacokinet. 2006, 45:235-252. 10.2165\/00003088-200645030-00002","journal-title":"Clin Pharmacokinet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2011.555781","article-title":"Bilateral macular ischemia and severe visual loss following trastuzumab therapy","volume":"50","author":"Saleh M","year":"2011","unstructured":"Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol. 2011, 50:477-478. 10.3109\/0284186X.2011.555781","journal-title":"Acta Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1280-1","article-title":"Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis","volume":"19","author":"Shinkai A","year":"2019","unstructured":"Shinkai A, Saito W, Hashimoto Y, Ishida S. Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis. BMC Ophthalmol. 2019, 19:267. 10.1186\/s12886-019-1280-1","journal-title":"BMC Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44303","article-title":"mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice","volume":"121","author":"Zhao C","year":"2011","unstructured":"Zhao C, Yasumura D, Li X, et al.. mTOR-mediated dedifferentiation of the retinal pigment epithelium initiates photoreceptor degeneration in mice. J Clin Invest. 2011, 121:369-383. 10.1172\/JCI44303","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0849-8","article-title":"Neratinib inhibits Hippo\/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells","volume":"38","author":"Dent P","year":"2019","unstructured":"Dent P, Booth L, Roberts JL, et al.. Neratinib inhibits Hippo\/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene. 2019, 38:5890-5904. 10.1038\/s41388-019-0849-8","journal-title":"Oncogene"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/416279b","article-title":"Tumour biology: herceptin acts as an anti-angiogenic cocktail","volume":"416","author":"Izumi Y","year":"2002","unstructured":"Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature. 2002, 416:279-280. 10.1038\/416279b","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/toxres\/tfab111","article-title":"Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice","volume":"11","author":"Tao G","year":"2022","unstructured":"Tao G, Dagher F, Ghose R. Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice. Toxicol Res (Camb). 2022, 11:184-194. 10.1093\/toxres\/tfab111","journal-title":"Toxicol Res (Camb)"},{"key":"ref15","article-title":"The effect of an individual\u2019s cytochrome CYP3A4 activity on docetaxel clearance","volume":"6(4)","author":"Hirth J","year":"2000","unstructured":"Hirth J, Watkins PB, Strawderman M, et al.. The effect of an individual\u2019s cytochrome CYP3A4 activity on docetaxel clearance\r\n. Clinical Cancer Research. 2000, 6(4):1255-1258.","journal-title":"Clinical Cancer Research"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/129087-suspected-neratinib-macular-toxicity-presenting-as-macular-telangiectasia-type-ii","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:01Z","timestamp":1707508081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/129087-suspected-neratinib-macular-toxicity-presenting-as-macular-telangiectasia-type-ii"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.33964","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}